which in our case could inhibit the conversion of valencene. For that reason we used a mutated version of BM3, which is called AIPLF. This variant is an enhanced version of the BM3 AIP version, which has a ten times better substrate oxidation rate for valencene than the wildtype BM3 and produces less byproduct when valencene concentration is saturated. Additionally to previous named benefits the AIPLF variant with